Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins

Nutrition and Metabolism

Volumn 11, Issue 1, 2014, Pages

  Wang, Liyun ^a   Sacks, Frank M ^a,b   Furtado, Jeremy D ^a   Ricks, Madia ^c   Courville, Amber B ^d   Sumner, Anne E ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

African Americans; ApoAI; ApoB lipoproteins; ApoCIII; Coronary heart disease; HDL; Insulin resistance; Visceral adipose tissue

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; CARBOHYDRATE DIET; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE TOLERANCE TEST; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; PROTEIN DIET; RACE DIFFERENCE;

EID: 84988353103     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-11-56     Document Type: Article

References (35)

1. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003, 163(4):427-436.
2. Jolly S, Vittinghoff E, Chattopadhyay A, Bibbins-Domingo K: Higher cardiovascular disease prevalence and mortality among younger blacks compared to whites. Am J Med 2010, 123(9):811-818.
3. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL: Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997, 43(12):2364-2378.
4. Guerrero R, Vega GL, Grundy SM, Browning JD: Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology (Baltimore, Md) 2009, 49(3):791-801.
5. Sumner AE, Cowie CC: Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 2008, 196(2):696-703.
6. Chow CC, Periwal V, Csako G, Ricks M, Courville AB, Miller BV 3rd, Vega GL, Sumner AE: Higher acute insulin response to glucose may determine greater free fatty acid clearance in African-American women. J Clin Endocrinol Metab 2011, 96(8):2456-2463.
7. Sumner AE, Micklesfield LK, Ricks M, Tambay AV, Avila NA, Thomas F, Lambert EV, Levitt NS, Evans J, Rotimi CN, Tulloch-Reid MK, Goedecke JH: Waist circumference, BMI, and visceral adipose tissue in white women and women of African descent. Obesity (Silver Spring, Md) 2011, 19(3):671-674.
8. Abbasi F, Brown BW, Lamendola C, McLaughlin T, Reaven GM: Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002, 40(5):937-943.
9. Tulloch-Reid MK, Hanson RL, Sebring NG, Reynolds JC, Premkumar A, Genovese DJ, Sumner AE: Both subcutaneous and visceral adipose tissue correlate highly with insulin resistance in African Americans. Obes Res 2004, 12(8):1352-1359.
10. Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, Meigs JB, Sutherland P, D'Agostino RB Sr, O'Donnell CJ, Fox CS: Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring, Md) 2010, 18(11):2191-2198.
11. Osei K: Metabolic syndrome in blacks: are the criteria right? Curr Diab Rep 2010, 10(3):199-208.
12. Ukegbu UJ, Castillo DC, Knight MG, Ricks M, Miller BV 3rd, Onumah BM, Sumner AE: Metabolic syndrome does not detect metabolic risk in African men living in the U.S. Diabetes Care 2011, 34(10):2297-2299.
13. Yu SS, Ramsey NL, Castillo DC, Ricks M, Sumner AE: Triglyceride-based screening tests fail to recognize cardiometabolic disease in African immigrant and African-American men. Metab Syndr Relat Disord 2013, 11(1):15-20.
14. Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM: Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011, 124(19):2065-2072.
15. Jensen MK, Rimm EB, Furtado JD, Sacks FM: Apolipoprotein C-III as a potential modulator of the association between HDL-Cholesterol and incident coronary heart disease. J Am Heart Assoc 2012, 1:e000232.
16. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 2000, 102(16):1886-1892.
17. Chivot L, Mainard F, Bigot E, Bard JM, Auget JL, Madec Y, Fruchart JC: Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Atherosclerosis 1990, 82(3):205-211.
18. Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F, Fruchart JC, Ducimetiere P: Apolipoproteins C-III and E in apoB-and non-apoBcontaining lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde. J Lipid Res 1996, 37(3):508-517.
19. Shin MJ, Kanaya AM, Krauss RM: Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 2008, 198(2):313-319.
20. Florez H, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Castillo-Florez S, Lee D, Goldberg R: Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. Atherosclerosis 2006, 188(1):134-141.
21. Sumner AE, Furtado JD, Courville AB, Ricks M, Younger-Coleman N, Tulloch-Reid MK, Sacks FM: ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women. Nutr Metab 2013, 10(1):73.
22. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298(3):309-316.
23. Mora S, Rifai N, Buring JE, Ridker PM: Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008, 118(10):993-1001.
24. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute: Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014, 371(1):22-31.
25. Adiels M, Olofsson SO, Taskinen MR, Boren J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28(7):1225-1236.
26. Choi SH, Ginsberg HN: Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 2011, 22(9):353-363.
27. Chen M, Breslow JL, Li W, Leff T: Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994, 35(11):1918-1924.
28. Dallinga-Thie GM, Groenendijk M, Blom RN, De Bruin TW, De Kant E: Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin. J Lipid Res 2001, 42(9):1450-1456.
29. Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NC: Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem 1998, 273(30):18959-18965.
30. Lam JK, Matsubara S, Mihara K, Zheng XL, Mooradian AD, Wong NC: Insulin induction of apolipoprotein AI, role of Sp1. Biochemistry 2003, 42(9):2680-2690.
31. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH: Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004, 114(10):1493-1503.
32. Caron S, Verrijken A, Mertens I, Samanez CH, Mautino G, Haas JT, Duran-Sandoval D, Prawitt J, Francque S, Vallez E, Muhr-Tailleux A, Berard I, Kuipers F, Kuivenhoven JA, Biddinger SB, Taskinen MR, Van Gaal L, Staels B: Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2011, 31(3):513-519.
33. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G: Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin EndocrinolMetab 2004, 89(8):3949-3955.
34. Pavlic M, Valero R, Duez H, Xiao C, Szeto L, Patterson BW, Lewis GF: Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol 2008, 28(9):1660-1665.
35. Miller BV 3rd, Patterson BW, Okunade A, Klein S: Fatty acid and very low density lipoprotein metabolism in obese African American and Caucasian women with type 2 diabetes. J Lipid Res 2012, 53(12):2767-2772.